Ardelyx, Inc. (ARDX) Stock Analysis — Probabli.AI
AI-powered analysis for ARDX (Ardelyx, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $5.97 · Market cap: $1.5B · AI outlook: Bullish
Ardelyx, Inc. is a promising biopharmaceutical company focusing on addressing unmet medical needs, especially in the kidney and gastrointestinal medicine sectors. Recent FDA fast track designations, successful clinical outcomes, and strong analyst support bolster the outlook. Despite some challenges related to cash burn and patents, Ardelyx's innovative pipeline and strategic partnerships make…
Probabilistic 1-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 1-year price estimates — P10: $5 / P50: $10 / P90: $18
- Ardelyx is well-positioned with its recent FDA fast track designation and expanded pipeline. Analyst consensus is overwhelmingly positive, suggesting potential strong performance ahead.
5-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 5-year price estimates — P10: $9 / P50: $22 / P90: $43
SWOT Highlights
- Strength: FDA fast track designation for a kidney drug
- Strength: Expanded pipeline with new drug acquisition
- Risk: High cash burn rate
- Risk: Uncertainty around patent challenges
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
7 Wall Street analysts rate ARDX a STRONG BUY with a mean price target of $15.14.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
ARDX forecast details · ARDX sentiment details · ARDX insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.